K nowing a patient's chance of developing an illness is central to all good medical decision-making as developing personalized treatment strategies requires estimating each patient's risk of developing that particular disease. [1] [2] [3] [4] [5] This risk-based principal underlies the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines for cholesterol-lowering statin drugs, 6, 7 which recommend using a patient's estimated cardiovascular disease (CVD) risk to guide primary CVD prevention. Risk has long played a central role in guiding aspirin use 8 and blood pressure treatment internationally, 9 but these recommendations produced considerable controversy, in part because critics noted that the associated risk score (the atherosclerotic CVD score, or atherosclerotic cardiovascular disease (ASCVD) score) had inconsistent results in some populations. 10 The inconsistency between populations is not surprising. Risk scores often are inconsistent between populations and time periods. 11, 12 One potential solution to this problem in the era of Big Data is to create risk scores using a health care system's own data instead of relying on externally developed scores from actively followed cohort studies. This approach could have several advantages. First, it eliminates the problem of results varying between populations, as the risk score would be calibrated to the population in which it will be used. Second, the tool could be updated whenever the local health care system finds it useful, instead of depending on the investigators of a particular cohort study. Third, the tool would use data from actual patients, not the research volunteers used in cohort studies, who can be decidedly nonrepresentative. Finally, the data in cohort studies are gathered in research settings 7 ; it is unclear how well these data reflect true clinical practice, especially as some variables (like blood pressure and smoking status) are measured less reliably in the usual outpatient setting. Higher-quality data collected in research settings could lead to risk scores with excellent discrimination in the original analyses, but worse in clinical practice.
Creating a risk score using a health care system's observed clinical data; however, also carries substantial risks. The lack of research-quality data could mean that a realworld risk score will predict events poorly. Missing data, for example from patients not receiving laboratory draws, could also limit the score's accuracy.
The US Department of Veterans Affairs (VA) is the country's largest integrated health care system and has been a leader in using the electronic health record (EHR) for clinical care. 13 This paper tests the feasibility of recreating the ASCVD risk score to the VA population using information available in the VA EHR. Although most directly relevant to statin use following the ACC/AHA guidelines, this work is intended to guide care for all of cardiovascular prevention. To do this, we developed 3 models of increasing data and analytic requirements for adapting the ASCVD tool to the VA population: Population Recalibrated, Regression Recalibrated, and the VA Risk Score for Cardiovascular Disease (VARS-CVD). The Population Recalibrated model adjusts for differences between the study cohort and the target population using population-level demographic information. These data would likely be easily available to health system leaders. The Regression Recalibrated method rescales individual-level ASCVD scores. The VARS-CVD model is fully refitted for all the ASCVD model predictors. 14 We compared the 3 models using common measures of calibration and discrimination. Calibration assesses how closely the predicted risk probabilities reflect true risk by comparing predicted outcomes to observed ones. Discrimination measures the ability of a risk prediction tool to distinguish between those who will and will not have an event during the follow-up period. Both could be impacted by using clinical EHR data. We hypothesized that recreating the scores with EHR data would improve calibration without dramatically harming clinical discrimination. This approach could provide a model for how other health systems can create risk scores that are evidence-based, practical for applied use, and calibrated to their own patients in many conditions using EHR data.
METHODS

Data Sources
We used national data from the outpatient, inpatient, labchem, pharmacy, vital signs, and health factors datasets from the VA; Medicare inpatient, MedPAR, carrier, and outpatient data files from Centers for Medicare and Medicaid Services; and data from the National Death Index (Supplementary Table 1 
Population
We identified all VA patients aged 45-80 who had no documented history of CVD or clinical heart failure, who had at least 2 outpatient visits to specific ambulatory care clinics during 2006 (Supplementary Table 2 , Supplemental Digital Content 1, http://links.lww.com/MLR/B445), and who were alive at the start of follow-up of January 1, 2007. We excluded patients on loop diuretics because of concern for undocumented Congestive Heart Failure. We excluded patients who died from a non-CVD cause of death during 2007, as this likely represents preexisting serious illness that would make primary prevention inappropriate. We did not exclude people who were on statins because we intend this risk score to have broader use than just statin decisions.
We randomly selected two thirds of the dataset to serve as a derivation cohort for model building and used the remaining third for validation. All reported results for prediction quality are from the validation cohort.
Risk Predictors
Our analyses focused on the variables in the ASCVD risk model (Supplementary Tables 3 
Outcome Variables
Our outcome was "hard" CVD events during the 5-year follow-up period from January 1, 2007 to December 31, 2011. Hard CVD events included the first occurrence of nonfatal myocardial infarction, Coronary Heart Disease death, fatal or nonfatal stroke, based on the 2013 ACC/AHA cholesterol guideline (Supplementary Table 6 , Supplemental Digital Content 1, http://links.lww.com/MLR/B445). 6 We used ICD9 diagnosis codes from inpatient admissions to define nonfatal events, including AMI 15 and stroke. 16, 17 Fatal CV events were defined using ICD10 codes from National Death Index data (I00-I99). We also examined a shorter period using 3 years of follow-up data (2007-2009) in sensitivity analyses, which did not improve model prediction.
Prediction Models
First, we computed the risk score reported by the American College of Cardiology/American Heart Association's (ASCVD) Score, which is derived from pooled cohort data and is the basis of current statin guidelines for primary CVD prevention. 6, 7 The ASCVD score was originally created from a pooled sample of 5 large National Institutes of Health-funded cohorts-the Framingham Study, the Framingham Offspring Study, Atherosclerosis Risk in Communities, Cardiovascular Health Study, and Coronary Artery Risk Development in Young Adults. 7 The standard ASCVD risk equation is as follows:
where IndX 0 B is the sum of the individual patient's covariate values multiplied by the coefficients from the ASCVD equation and MeanX 0 b is the race and sex-specific overall mean "coefficient X value" sum. Thus, the estimated 5-year risk of a first event is calculated by 1 minus the survival rate at 5 years, raised to the power of the exponent of IndX 0 b minus MeanX 0 b. The published ASCVD score uses 10 years of follow-up. We computed 5-year ASCVD risk scores using the published regression coefficients, but with the intercept coefficient (b-0) based on 5 years of follow-up events obtained directly from the tool developers.
Next, we considered 3 different methods for recalibrating the ASCVD model for the VA patient population. The Population Recalibrated method mimics a situation in which population averages are available but individual patient-level data are not, for example, when using technical reports instead of individual data. We first computed the 5-year VARS survival rate within each sex/race group for our cohort. Then we calculated the MeanX 0 b for each sex/race group in VARS using our population-level averages using the functional form and the estimated hazard ratios from the published ASCVD risk equations. The Regression Recalibrated technique was designed as a simple method for recalibration that assumes the basic relationships between specific variables and risk is stable, but overall risk varies between populations. This technique keeps the basic risk factor coefficients unchanged, possibly improving comparability and limiting overfitting. It is also consistent with a model for risk prediction that assumes the effect of these risk factors is biologically causal and hence relatively stable between populations. We used the ASCVD 5-year score as a predictor in a logistic regression model to create the Regression Recalibrated risk score.
where b 0 and b 1 are estimated in our sample and X is the ASCVD score calculated using the ASCVD coefficients, 5-year survival rate, and values for MeanX 0 B (citation). The model was fit separately for men and women in the derivation cohort. The resulting regression intercepts and slopes were used to create transformations of the ASCVD scores for patients.
Finally, we created a fully refitted model that reestimated the effect size of each of the ASCVD variables. This was the prespecified "VARS-CVD" model. This model used sex-specific 5-year CVD logistic regression risk equations fit on the derivation portion of our dataset. In all 3 recalibrated models, we created separate models for men and women, and included a main effect term for African American in both the male and female regression models. In comparison, the ASCVD score created 4 models for sex and race. We were limited by having relatively few African American women in our dataset. We also do not know precisely which interactions were tested for the ASCVD score, so we could not mirror them. We did not create separate models for other terms because this has not been done historically in most risk scores and because the effects of the individual variables on prediction (historically or in our model) did not seem large enough to make it appropriate.
For all 3 recalibrated models, to generalize our 5-year results to other published results using 10-year risk scores, we estimated 10-year risk based on our 5-year risk score using the following calculation:
Pr CV Event in 10y j age ð Þ ¼ Pr CV event in 5y j age ð Þ þ 1À Pr ðCV event in 5y j ageÞ ð Þ Â Pr CV event in 5y j age þ 5 ð Þ ½ :
Analysis
For each risk score we report the c-statistic, the HosmerLemeshow Goodness of Fit statistic (GoF), and the Brier Score to quantify discrimination (ability of a risk prediction equation to distinguish between those who do and do not have an event during the follow-up period) and calibration (how closely the predicted probabilities reflect true risk) within the validation cohort. We calculated cut-points of our 5-year risk score to differentiate low, medium, and high-risk. We defined low-risk as <10-year ASCVD score cutoff of 7.5%, which guides the current cholesterol guidelines. 6 We defined high risk as greater than the commonly used cut-point of 20% 10-year risk. 18, 19 We then categorized samples for each risk score into low (10-year CVD risk of under 7.5%), medium (about a 7.5%-20%), or high ( > 20%) risk. We then found analogous 5-year cutpoints that resulted in the same percent of patients in each risk group. The resulting 5-year cut-points were <3% (low risk), 3%-9% (medium risk), and >9% (high risk).
In sensitivity analyses described in Supplement 4, Supplemental Digital Content 1 (http://links.lww.com/MLR/ B445), we examined the potential impact of uncaptured events where a patient has a nonfatal cardiovascular event at a non-VA facility that is paid for by non-VA sources. We also looked at a variety of prespecified subgroups.
The study was approved by the Institutional Review Board, ROC Receiver operating characteristic of the VA Ann Arbor Healthcare System with a waiver of informed consent. Table 1 summarizes patient baseline characteristics. Compared with the pooled cohort sample of 5 large NIHfunded cohorts used to create the ASCVD score and other commonly used risk scores, the VA Risk Score (VARS) cohort is much larger, older, predominantly male, has higher diabetes prevalence and is on more medicines for blood pressure and cholesterol (Supplementary Table 7 , Supplemental Digital Content 1, http://links.lww.com/MLR/B445). 7 There were no differences between the derivation and validation cohorts.
RESULTS
Description of Variables Examined
The exclusions are described in detail in Supplementary 
Assessment of Prediction Models
Overall, discrimination was similar across the models within each sex, but their calibration to the VA population varied dramatically ( Table 2 ). The models had greater c-statistics (area under the ROC curve, a measure of discrimination) in women than in men. Within each sex, the ASCVD score had the lowest c-statistic and the VARS-CVD the largest, although the difference was small. The Population and Regression Recalibrated methods resulted in c-statistics identical to the ASCVD score in men. In women, the Regression Recalibrated had the same c-statistic as the ASCVD score, but the Population Recalibrated method had a very slight improvement. The model parameters for the VARS-CVD model are in Supplementary Table 10, Supplemental Digital Content 1 (http://links.lww.com/MLR/B445).
The improvement in calibration between predicted risk probabilities and the recalibrated tools was more dramatic ( Table 2 ). The standard ASCVD score substantially overestimated CVD events with an average predicted event rate Table 2 ). Most of this overestimation was in those with higher observed risk (Fig. 1) . This was especially true in the Population Recalibrated system. The results for the women were less dramatic. The ASCVD score only slightly overestimated event rates (0.023 average predicted events vs. 0.021 observed, per 5 years; GoF, 49.0). The Population Recalibrated had a minimal effect on the discrimination and made calibration substantially worse, especially at the higher values (Table 2 and Fig. 1 ).
(the GoF statistic cannot be directly compared between the models for men and women due to differences in sample size.) Results were very similar in multiple subgroups (Supplementary Table 11 , Supplemental Digital Content 1, http://links.lww.com/MLR/B445).
RISK RECLASSIFICATION
The clinical implications of improved calibration are seen in the dramatic effect on patient risk reclassification (Table 3 and Supplementary Table 12 , Supplemental Digital Content 1, http://links.lww.com/MLR/B445). Of the 189,491 participants classified as high CVD risk (5-year risk >9%, estimated 10-year CVD risk >20%) by the ASCVD score, 62.6% were reclassified down to medium risk (5-year risk between 3% and 9%, estimated 10-year CVD risk between 7.5% and 20%) by VARS-CVD; of the 233,450 classified as medium risk by ASCVD, 19.9% were reclassified as low risk (5-year risk <3%, estimated 10-year CVD risk <7.5%) and 0.2% to high risk by VARS-CVD; and of the 81,090 participants classified as low CVD risk by the ASCVD tool, 3.6% were reclassified as medium risk (by VARS-CVD (Table 3) . The reclassification of patients from high to medium risk was similar when comparing the original ASCVD score to the other scores; reclassification between the VARS-CVD, Population Recalibrated, and Regression Recalibrated scores was less common (Table 3 and Supplementary Table 12 , Supplemental Digital Content 1, http://links.lww. com/MLR/B445).
Of the 422,941 people who would be recommended statin use by the ASCVD criteria, 46,508 (11.0%) actually have a <7.5% chance of having a heart attack or stroke in 10 years and should not be recommended to start a statin. Cut-points use 5-year cut-points of 3% and 9% 5-year risk, which closely approximate the 7.5% and 20% cut-points seen in current guidelines. ASCVD indicates atherosclerotic cardiovascular disease; VARS-CVD, VA Risk Score for Cardiovascular Disease; VA, Veterans Affairs.
The locally developed risk scores predicted lower event rates for almost all participants than the ASCVD score. This included reclassifying almost 20 times more people to lower risk groups than higher risk groups (Table 3, Supplemental Table 13 
Missing and Misclassified Data
Missing data, imputation, and misclassified results, including from uncaptured cardiovascular events, had small effects on the models. Full details of this evaluation are in Supplementary Tables 13-17 
DISCUSSION
We found that a large managed care organization can use their own EHRs and administrative outcome data to create a CVD risk prediction score with substantial advantages over those developed in traditional cohort studies. The VARS-CVD score is much better calibrated than the externally developed ASCVD score. 7, 12 The ASCVD score, developed from data pooled from 5 cohort studies, had similar statistical discrimination to our internally developed VARS-CVD, but systematically overestimated the observed risk in our cohort by almost 60%. 20 Our findings have substantial implications for riskbased prevention of CVD. CVD risk prediction is central to the 2013 ACC/AHA Clinical Practice Guidelines on the Treatment of Blood Cholesterol. These guidelines remain controversial, in part due to observed overprediction when the ASCVD score was examined in some study populations. 20 However, it is well-established that risk scores developed in one population often mispredict in other populations as people always have risk factors that are not easily measured. 12 For example, exercise and life stress are established risk factors, but are vexingly difficult to measure. 21 Unfortunately, current clinical research continues to look for a single, "correct" risk score 22, 23 and clinical practice uses only 1 risk score. 6, 22 This study demonstrates how the cholesterol guidelines, and other risk-based guidelines, could instead be easier to use and more accurate if we create many local risk scores. Our results indicate that instead of accepting calibration error or ignoring overall risk altogether we should use locally recalibrated or newly developed risk scores created from EHRs. Further, the real-world data have strengths that may at first seem like weaknesses. For example, large cohort studies usually measure blood pressure averaging multiple measures following careful protocols. 7 In contrast, an internally developed risk score uses the risk factor how it's measured in practice.
EHR-based risk prediction scores like VARS-CVD have other advantages over cohort-derived scores. An organization's risk profile can change from population-wide trends and changing demographics. As we used information that is easily available (Table 4) , organizations can develop and update risk scores independently. These results can be integrated into local decision support tools based on their needs. EHR-based scores can also have much larger populations. Although our patient population was 95% men, there were still 6 times more women in our sample as in the ASCVD score development population. Further, advances in wearable technology, genetics and EHRs could soon provide dramatic advances in risk prediction unavailable in existing cohorts. 24, 25 We used 3 different recalibration techniques, each designed to approximate a different real-world situation. The first, Population Recalibrated, is meant to resemble how health system managers, with easy access to population-level descriptive information about their patients could roughly approximate their patient's risk. The second, Regression Recalibrated, used a simple logistic regression between the results of the ASCVD score and the observed outcome in our database. This keeps the basic risk ratios unchanged, potentially improving comparability and limiting overfitting. Although better than using the ASCVD score, these models had poor calibration. Finally, in the full recalibration technique (VARS-CVD), we used the individual predictors and recalibrated the entire model. We had wondered whether the simpler recalibration techniques would be "good enough" for organizations, but found that their miscalibration was quite large.
The strengths of this study-including the use of clinical data-also lead to its weaknesses. Important data were missing for some patients. We think this is partly why our study's discrimination was not better than previous scores.
Our study used administrative data for identifying outcomes, as opposed to chart review or full adjudication, which will create some estimation errors. 26, 27 Although there are advantages to fully adjudicating outcomes, they are also prone to capture minor events that have unclear clinical importance, such as increases in troponin. Further, CVD mortality, especially, is known to be overestimated in administrative databases. 28 This overestimation makes our com/MLR/B445). Finally, ideally we would have tested our risk score on patients from after the score was completed, rather than the same time period. This was not practical due to data limitations.
Although other scores were based on 10 years of followup, we developed our score using 5-year follow-up. We did this for 3 reasons: (1) to minimize the impact of changes in lipid and blood pressure medication that might be made during follow-up of an initial disease-free cohort, (2) we think this is a more reasonable basis for decision-making as decisions should probably be reassessed at least every 3-5 years, and (3) the full 10 years of data are not fully reliable in our dataset. We cannot find a clinical reason why 10 years became common many years ago.
This work has policy and clinical implications. We have shown that clinical risk scores can be made efficiently within a single EHR. This could be done at many other managed care organizations and for many other clinical conditions. As EHRs improve, scores like the VARS-CVD score can easily be improved and recalibrated to new populations. As "Big Data" becomes more central to patient self-management, work like this can point the way toward how these tools can be used in clinical practice, preventing CVD events while guiding statin use for patients who are more likely to benefit.
